Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta

被引：27

作者：

Chan, Jerry K. Y. ^{[1
,2
,3
,4
]}

Gotherstrom, Cecilia ^{[5
,6
]}

机构：

[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Expt Fetal Med Grp, Dept Obstet & Gynecol, Singapore 117595, Singapore

[2] Natl Univ Singapore, Singapore 117548, Singapore

[3] KK Womens & Childrens Hosp, Dept Reprod Med, Singapore 228899, Singapore

[4] Duke Natl Univ Singapore Grad Med Sch, Canc & Stem Cell Biol, Singapore, Singapore

[5] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Obstet & Gynecol, Stockholm, Sweden

[6] Karolinska Inst, Ctr Hematol & Regenerat Med, Stockholm, Sweden

来源：

FRONTIERS IN PHARMACOLOGY | 2014年 / 5卷

基金：

英国医学研究理事会;

关键词：

prenatal transplantation; in utero transplantation; intrauterine transplantation mesenchymal stem cells; fetal stem cells; osteogenesis imperfecta; IN-UTERO TRANSPLANTATION; BONE-MARROW; INTRAUTERINE TRANSPLANTATION; MUSCLE DIFFERENTIATION; PRECURSOR CELLS; STROMAL CELLS; FETAL BLOOD; DONOR AGE; CHILDREN; THERAPY;

D O I：

10.3389/fphar.2014.00223

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Osteogenesis imperfecta (OI) can be a severe disorder that can be diagnosed before birth. Transplantation of mesenchymal stem cells (MSC) has the potential to improve the bone structure, growth, and fracture healing. In this review, we give an introduction to OI and MSC, and the basis for pre-and postnatal transplantation in OI. We also summarize the two patients with OI who have received pre-and postnatal transplantation of MSC. The findings suggest that prenatal transplantation of allogeneic MSC in OI is safe. The cell therapy is of likely clinical benefit with improved linear growth, mobility, and reduced fracture incidence. Unfortunately, the effect is transient. For this reason, postnatal booster infusions using same-donor MSC have been performed with clinical benefit, and without any adverse events. So far there is limited experience in this specific field and proper studies are required to accurately conclude on clinical benefits of MSC transplantation to treat OI.

引用

页数：6

共 62 条

[1]

Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung [J].